Literature DB >> 22511543

Muscarinic type 3 receptor induces cytoprotective signaling in salivary gland cells through epidermal growth factor receptor transactivation.

Mikihito Kajiya1, Isao Ichimonji, Christine Min, Tongbo Zhu, Jun-O Jin, Qing Yu, Soulafa A Almazrooa, Seunghee Cha, Toshihisa Kawai.   

Abstract

Muscarinic type 3 receptor (M3R) plays a pivotal role in the induction of glandular fluid secretions. Although M3R is often the target of autoantibodies in Sjögren's syndrome (SjS), chemical agonists for M3R are clinically used to stimulate saliva secretion in patients with SjS. Aside from its activity in promoting glandular fluid secretion, however, it is unclear whether activation of M3R is related to other biological events in SjS. This study aimed to investigate the cytoprotective effect of chemical agonist-mediated M3R activation on apoptosis induced in human salivary gland (HSG) cells. Carbachol (CCh), a muscarinic receptor-specific agonist, abrogated tumor necrosis factor α/interferon γ-induced apoptosis through pathways involving caspase 3/7, but its cytoprotective effect was decreased by a M3R antagonist, a mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (ERK) inhibitor, a phosphatidylinositol 3-kinase/Akt inhibitor, or an epidermal growth factor receptor (EGFR) inhibitor. Ligation of M3R with CCh transactivated EGFR and phosphorylated ERK and Akt, the downstream targets of EGFR. Inhibition of intracellular calcium release or protein kinase C δ, both of which are involved in the cell signaling of M3R-mediated fluid secretion, did not affect CCh-induced ERK or Akt phosphorylation. CCh stimulated Src phosphorylation and binding to EGFR. A Src inhibitor attenuated the CCh/M3R-induced cytoprotective effect and EGFR transactivation cascades. Overall, these results indicated that CCh/M3R induced transactivation of EGFR through Src activation leading to ERK and Akt phosphorylation, which in turn suppressed caspase 3/7-mediated apoptotic signals in HSG cells. This study, for the first time, proposes that CCh-mediated M3R activation can promote not only fluid secretion but also survival of salivary gland cells in the inflammatory context of SjS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22511543      PMCID: PMC3382834          DOI: 10.1124/mol.111.077354

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  54 in total

Review 1.  Conventional therapy of Sjogren's syndrome.

Authors:  Clio P Mavragani; Haralampos M Moutsopoulos
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667

Review 2.  Muscarinic receptor subtypes in the alimentary tract.

Authors:  G Tobin; D Giglio; O Lundgren
Journal:  J Physiol Pharmacol       Date:  2009-03       Impact factor: 3.011

Review 3.  Sjögren's syndrome: an old tale with a new twist.

Authors:  Byung Ha Lee; Mauro A Tudares; Cuong Q Nguyen
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2009-02-14       Impact factor: 4.291

4.  Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study.

Authors:  L D Locati; P Bossi; F Perrone; P Potepan; F Crippa; L Mariani; P Casieri; M Orsenigo; M Losa; C Bergamini; C Liberatoscioli; P Quattrone; R G Calderone; G Rinaldi; S Pilotti; L Licitra
Journal:  Oral Oncol       Date:  2008-09-18       Impact factor: 5.337

Review 5.  Crosstalk between G-protein-coupled receptors and epidermal growth factor receptor in cancer.

Authors:  Neil E Bhola; Jennifer R Grandis
Journal:  Front Biosci       Date:  2008-01-01

6.  Distinct pathways of ERK activation by the muscarinic agonists pilocarpine and carbachol in a human salivary cell line.

Authors:  Alan L Lin; Bing Zhu; WanKe Zhang; Howard Dang; Bin-Xian Zhang; Michael S Katz; Chih-Ko Yeh
Journal:  Am J Physiol Cell Physiol       Date:  2008-04-02       Impact factor: 4.249

7.  Human submandibular gland (HSG) cell line as a model for studying salivary gland Ca2+ signalling mechanisms.

Authors:  K Nagy; V Szlávik; G Rácz; G Ovári; J Vág; G Varga
Journal:  Acta Physiol Hung       Date:  2007-12

Review 8.  Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia.

Authors:  L S Steelman; S L Abrams; J Whelan; F E Bertrand; D E Ludwig; J Bäsecke; M Libra; F Stivala; M Milella; A Tafuri; P Lunghi; A Bonati; A M Martelli; J A McCubrey
Journal:  Leukemia       Date:  2008-03-13       Impact factor: 11.528

9.  Functional epitope of muscarinic type 3 receptor which interacts with autoantibodies from Sjogren's syndrome patients.

Authors:  N-Y Koo; J Li; S-M Hwang; S-Y Choi; S J Lee; S-B Oh; J-S Kim; E B Lee; Y W Song; K Park
Journal:  Rheumatology (Oxford)       Date:  2008-04-09       Impact factor: 7.580

10.  Mitogen-activated protein kinase up-regulation and activation during rat parotid gland atrophy and regeneration: role of epidermal growth factor and beta2-adrenergic receptors.

Authors:  Howard Dang; James J Elliott; Alan L Lin; Bing Zhu; Michael S Katz; Chih-Ko Yeh
Journal:  Differentiation       Date:  2007-12-20       Impact factor: 3.880

View more
  10 in total

1.  Effect of the M1 Muscarinic Acetylcholine Receptor on Retinal Neuron Number Studied with Gene-Targeted Mice.

Authors:  Panagiotis Laspas; Jan J Sniatecki; Christoph Brochhausen; Andreas Steege; Evgeny Goloborodko; Marcin L Kordasz; Franz H Grus; Norbert Pfeiffer; Adrian Gericke
Journal:  J Mol Neurosci       Date:  2015-02-28       Impact factor: 3.444

2.  M3 mAChR-mediated IL-8 expression through PKC/NF-κB signaling pathways.

Authors:  Zu-Peng Xu; Yun Song; Kai Yang; Wei Zhou; Li-Na Hou; Liang Zhu; Hong-Zhuan Chen; Yong-Yao Cui
Journal:  Inflamm Res       Date:  2014-02-13       Impact factor: 4.575

3.  Activation of M3 muscarinic receptor by acetylcholine promotes non-small cell lung cancer cell proliferation and invasion via EGFR/PI3K/AKT pathway.

Authors:  Ran Xu; Chao Shang; Jungang Zhao; Yun Han; Jun Liu; Kuanbing Chen; Wenjun Shi
Journal:  Tumour Biol       Date:  2015-05-12

4.  Interleukin-6 inhibits apoptosis of exocrine gland tissues under inflammatory conditions.

Authors:  Jing Zhou; Jun-O Jin; Ekta S Patel; Qing Yu
Journal:  Cytokine       Date:  2015-08-05       Impact factor: 3.861

5.  Effect of brimonidine, an α2 adrenergic agonist, on human meibomian gland epithelial cells.

Authors:  Xi Han; Yang Liu; Wendy R Kam; David A Sullivan
Journal:  Exp Eye Res       Date:  2018-02-13       Impact factor: 3.467

6.  The effect of deficient muscarinic signaling on commonly reported biochemical effects in schizophrenia and convergence with genetic susceptibility loci in explaining symptom dimensions of psychosis.

Authors:  Costa Vakalopoulos
Journal:  Front Pharmacol       Date:  2014-12-15       Impact factor: 5.810

7.  Epidermal growth factor receptor transactivation is required for mitogen-activated protein kinase activation by muscarinic acetylcholine receptors in HaCaT keratinocytes.

Authors:  Wymke Ockenga; Sina Kühne; Simone Bocksberger; Antje Banning; Ritva Tikkanen
Journal:  Int J Mol Sci       Date:  2014-11-21       Impact factor: 5.923

8.  Cryopreserved clumps of mesenchymal stem cell/extracellular matrix complexes retain osteogenic capacity and induce bone regeneration.

Authors:  Souta Motoike; Mikihito Kajiya; Nao Komatsu; Manabu Takewaki; Susumu Horikoshi; Shinji Matsuda; Kazuhisa Ouhara; Tomoyuki Iwata; Katsuhiro Takeda; Tsuyoshi Fujita; Hidemi Kurihara
Journal:  Stem Cell Res Ther       Date:  2018-03-21       Impact factor: 6.832

9.  PKD1 mediates negative feedback of PI3K/Akt activation in response to G protein-coupled receptors.

Authors:  Yang Ni; James Sinnett-Smith; Steven H Young; Enrique Rozengurt
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

10.  Sulforaphane Improves Ischemia-Induced Detrusor Overactivity by Downregulating the Enhancement of Associated Endoplasmic Reticulum Stress, Autophagy, and Apoptosis in Rat Bladder.

Authors:  Huai-Ching Tai; Shiu-Dong Chung; Chiang-Ting Chien; Hong-Jeng Yu
Journal:  Sci Rep       Date:  2016-11-08       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.